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Antiphospholipid antibodies (aPL), the serological hallmark of antiphospholipid syndrome
(APS), are a heterogeneous group of autoantibodies raised against circulating blood
proteins. Of these proteins, the phospholipid-binding b2-glycoprotein I (β2GPI) is
considered to be the main autoantigen in APS. Indeed, IgG antibodies targeting b2GPI
(ab2GPI) directly cause both thrombosis and pregnancy morbidity in several mouse
models. While antibodies raised against all five domains of b2GPI have been reported,
a subgroup of IgG ab2GPI raised against the first domain (DI) of b2GPI (aDI), strongly
correlate with thrombotic APS, and drive thrombosis and pregnancy loss in vivo.
Few studies have focused on determining the type of IgG subclass(es) for aPL. The
subclass of an antibody is important as this dictates the potential activity of an antibody;
for example, IgG1 and IgG3 can fix complement better and are able to cross the
placenta compared to IgG2 and IgG4. It is unknown what subclass IgG aDI are,
and whether they are the same as ab2GPI. To determine IgG subclass distribution
for ab2GPI and aDI, we purified total IgG from the serum of 19 APS patients with
known ab2GPI and aDI activity. Using subclass-specific conjugated antibodies, we
modified our established in-house ab2GPI and aDI ELISAs to individually measure
IgG1, IgG2, IgG3, and IgG4. We found that while IgG1, IgG2, and IgG3 ab2GPI levels
were similar, a marked difference was seen in IgG subclass aDI levels. Specifically,
significantly higher levels of IgG3 aDI were detected compared to IgG1, IgG2, or IgG4
(p < 0.05 for all comparisons). Correlation analysis of subclass-specific ab2GPI vs.
aDI demonstrated that IgG3 showed the weakest correlation (r = 0.45, p = 0.0023)
compared to IgG1 (r = 0.61, p = 0.0001) and IgG2 (r = 0.81, p = 0.0001). Importantly,
total subclass levels in IgG purified from APS and healthy serum (n = 10 HC n = 12
APS) did not differ, suggesting that the increased IgG3 aDI signal seen in APS-derived
IgG is antigen-specific. To conclude, our data suggests that aDI show a different
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IgG subclass distribution to ab2GPI. Our results highlight the importance of aDI testing for
patient stratification and may point toward differential underlying aPL-driven pathogenic
processes that may be subclass restricted.
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INTRODUCTION
Antiphospholipid Syndrome is an autoimmune rheumatic
disorder with an estimated population prevalence of between 0.3
and 1% of the population (1), with a female predominance. Often
presenting in association with systemic lupus erythematosus
(SLE, secondary APS), APS is the commonest cause of acquired
hypercoagulability, accounting for one in six strokes in patients
under 50 years old (2), one in nine heart attacks (3), and
associated with an almost 3-fold greater risk of atherosclerosis,
even in the absence of SLE (primary APS), compared to matched
controls (4).
Antibodies play a key role in the pathogenesis of APS. The
accepted international classification criteria for the disease (5)
require positive tests for antiphospholipid antibodies (aPL) on
at least two occasions, at least 12 weeks apart. There are three
different tests routinely used to detect aPL in clinical practice.
Two of these are enzyme-linked immunosorbent assays (ELISAs)
for IgG and IgM antibodies to cardiolipin (aCL ELISA) or β2
glycoprotein I (aβ2GPI ELISA), while the third is a functional test
that detects the effect of aPL on clotting time in the presence or
absence of excess phospholipid (the lupus anticoagulant or LA
test). aCL and aβ2GPI antibodies are found in various isotypes.
Though only IgG and IgM measurements are defined in the
classification criteria (5), there is increasing interest in the role
played by IgA aPL. Despite this, the IgG isotype best correlates
with clinical events in patients (6–8) and is the most often studied
in vitro and in vivo (9–14).
There is extensive evidence from clinical studies and mouse
models of both thrombosis and pregnancy loss (15–19) that
IgG aPL play a direct pathogenic role in APS. However, not all
aPL are equally pathogenic. McNeil et al (20) showed that non-
pathogenic aPL found in healthy people could bind both neutral
and anionic PL without the need for a co-factor, whereas aPL
from patients with APS showed preferential binding to anionic
PL but required the presence of the serum co-factor β2GPI.
Subsequently, it was shown that these pathogenic aPL could
bind β2GPI in the absence of PL. β2GPI has five domains, and
multiple studies have shown that antibodies to the N-terminal
domain (Domain I or DI, anti-DI antibodies or aDI) are most
closely linked to development of thrombosis (12, 13, 21–24).
Our group has shown that when IgG from patients with APS
is fractionated into aDI-rich and aDI-poor fractions by affinity
purification on a DI column and the fractions used to stimulate
thrombosis in amousemodel of APS, the thrombogenic potential
is concentrated in the aDI fraction (25). In the same mouse
model, we also showed that recombinant DI can block induction
of thrombosis by IgG from patients with APS IgG antibodies
are produced in four subclasses: IgG1, IgG2, IgG3, and IgG4
(26). Each of these subclasses has different avidities, affinities
and abilities, for example IgG1 and IgG3 can cross the placenta
whilst IgG2 and IgG4 cannot. They also have different structures,
with IgG3 displaying a far longer hinge region than the other
subclasses. Their ability to interact with Fc receptors and their
affinity for those receptors also differs, whilst their alternative
structures lend themselves to different kinetics in serum, with
IgG3 displaying a range of half-lives (27). In SLE, there is
literature showing that IgG antibodies to key autoantigens are
concentrated in certain subclasses, with confounding results in
some cases. For example, Zahir et al. (28) studied 120 SLE
patients and showed that IgG3 anti-nucleosome antibodies were
present at high levels in active but not inactive SLE, rose
during flares of disease activity and showed a particularly close
association with nephritis. In contrast, Ravirajan et al. (29)
showed that in 31 patients with SLE, anti-nucleosome were
predominantly IgG2, anti-dsDNA antibodies were IgG1 and
IgG3, and anti-heparan sulfate were IgG2 and IgG3. There
is also a precedent for investigating IgG subclass distribution
in APS with studies examining the subclass distribution of
IgG aCL (30, 31), which seemingly appear to be of all four
subclasses but with a potentially pathogenic predominance for
IgG2 and IgG4. Previous research had suggested that IgG1 or
IgG2 predominate for aβ2GPI (32, 33), however, no-one has
investigated the subclass distribution of patient antibodies for
IgG aDI subclasses.
This led us to test whether the more pathogenic aDI subgroup
of aβ2GPI has a different subclass distribution compared to
aβ2GPI as a whole.
METHODOLOGY
Patients and Controls
Serum was obtained from 19 patients with APS and 5 healthy
controls (HC). Serum samples were collected by informed
consent following local institutional ethical approval from 19
patients from 2 centers: University College London [London,
UK], University of Istanbul [Istanbul, Turkey]. All 19 patients
fulfilled the revised classification criteria for APS (5).
IgG Purification
Polyclonal IgG was purified from serum of patients and healthy
controls as follows. Serum was diluted with physiological
phosphate buffer (pH 7.4) and run through a protein G sepharose
column (Pierce) before elution with 0.1M Glycine (pH 2.7) and
neutralization with 1M Tris buffer. Eluted IgG was desalted
and dialysed in physiological phosphate buffer (pH 7.4) using
a centrifugal concentrator. Samples were quantified by BCA
(Pierce).
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Establishing an ELISA Method for Direct
Comparison of IgG Subclass Levels Using
Optical Density (OD) Units
Determination of the appropriate conditions for detecting all
four IgG subclasses was carried out using our in-house whole
IgG ELISA. Briefly, anti- human IgG (Sigma, I8885) is coated
at 400 ng/ml on half a maxisorp plate, the other half coated
with PBS alone. Samples are diluted in PBS, plates are washed 3
times before application of sample with PBST (0.1%). Secondary
antibody (anti-human IgG, HRP Conjugated) was applied at
1:1000 and incubated for 1 h at room temperature. Substrate
was warmed to room temperature and applied to the plate post
washing (100 µl) for 30min. Plates were stopped with acid
and read at 450 nM. Specificity for subclass was achieved using
subclass specific HRP conjugated secondary antibodies (Sigma).
Secondary antibody concentrations were determined using a
serum standard of known subclass composition. All secondary
antibodies were diluted to give OD values matching the expected
outcome from the known serum.
Goat anti-human IgG against the Fc portion (I8885, Sigma)
was used to coat maxisorp plates (400 ng/ml) overnight at 4◦C.
Plates were blocked with 2% BSA/PBS for 1 h at 37◦C, and the
commercial serum sample loaded at a dilution of 1:100000 in 1%
BSA/PBS for 1 h at room temperature (RT). Detection was carried
out using specific mouse anti-human secondary antibodies at a
range of values from 1:1000 to 1:80000 for 1 h at RT. Optimal
concentrations were as follows: anti-IgG1 at 1:1000, anti-IgG2
at 1:2000, anti-IgG3 at 1:10000 and anti-IgG4 at 1:80000. Plates
were washed and substrate added and developed in the dark for
10min. The reaction was stopped with 1% HCl and plates were
read at 450nm.
Measurement of Total IgG1, IgG2, IgG3,
and IgG4 in Purified IgG Samples
In order to be sure that differences between samples in the
amount of each IgG subclass binding to β2GPI or DI were indeed
antigen-specific findings and due to biasing of an individual
subclass, we carried out an ELISA to measure total IgG1, IgG2,
IgG3, or IgG4. In essence, this assay was the reverse of our whole
IgG ELISA, as described above. Four separate lanes of a maxisorp
plate were coated with mouse anti-human IgG1, IgG2, IgG3,
or IgG4 respectively. After blocking, purified IgG samples from
patients and controls were diluted to 500µg/ml in 1% BSA/PBS
and added to the plates, followed by incubation for 1 h at 37◦C.
Anti-human IgG secondary antibody conjugated to HRP (A6029,
Sigma) was added for 1 h at 37 ◦C. Substrate was added for
10min, the reaction was stopped with 1% HCL and OD was read
at 450nm. We compared OD values obtained from 10 HC and 12
APS patients.
aβ2GPI Subclasses ELISA
To measure IgG subclass specific aβ2GPI, we employed our
in-house aβ2GPI ELISA (35). Plates were prepared by coating
overnight with 4µg/ml of commercial purified human β2GPI at
4◦C (Enzyme Research Laboratories). Plates were then blocked
for 1 h at 37◦C with 2% BSA/PBS. Purified IgG samples from
patients and controls were prepared in 1% BSA/PBS at a protein
concentration of 500µg/ml. Samples were applied to the plate for
1 h before washing with PBS Tween (0.01%) and subclass specific
secondary antibodies (as established above) applied. Secondary
antibodies were diluted to the levels determined against the
calibrant material. Incubation with secondary antibody was for
1 h before washing and application of substrate for 15min,
followed by addition of 1% HCl to stop the reaction. Samples
were read at 450 nm. Binding for the individual subclasses was
compared. For each patient, all four secondary antibodies against
the four IgG subclasses were tested on the same plate.
aDI Subclasses ELISA
Similarly to the aβ2GPI assay, we utilized our in-house aDI
ELISA to measure IgG subclass specific aDI (34). The assay
was performed in exactly the same manner as per our aβ2GPI
ELISA, with the exception of the DI plates being coated with
10µg/ml of folded, conformationally correct DI for 2 h at 37◦C.
For each patient, all four secondary antibodies against the four
IgG subclasses were tested on the same plate.
Statistical Analysis
Statistical analysis was carried out using Prism V5.0. We
performed a 1 way ANOVA with a Kruskal-Wallis post
test to determine significant differences between IgG subclass
distributions. Linear regression analysis was carried out for
correlating subclasses between the two antigens, β2GPI and DI.
RESULTS
Samples from 19 different patients with APS were tested. Their
clinical and serological characteristics are shown in Table 1.
Twelve patients with APS had a history of vascular thrombosis
(VT) only, four had experienced pregnancymorbidity (PM) only,
one had VT and PM and two had catastrophic antiphospholipid
syndrome (CAPS).
The Pattern of IgG Subclass Detection Is
Different for aβ2GPI Compared to aDI
All 19 APS samples tested positive for aβ2GPI, 18 of which were
positive for aDI. The mean activity for all samples is shown in
Table 1.
TABLE 1 | This table shows the characteristics of the patients and healthy
controls included in the study.
APS HC
Age 36.8 (11.8) 33.3 (8.5)
Sex 12F, 6M 3F 1M
aβ2GPI 77.7 (30.4) –
aDI 45.19 (35.9) –
Other ARD 11 –
LA 13 –
Mean age, aβ2GPI and aDI levels are shown, with standard deviations in parentheses.
aβ2GPI positivity cut off: 8 GBU, aDI positivity cut off: 10 GDIU.
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Figures 1A,B show the relative percentages of subclass for
each antigen (1A, aβ2GPI and 1B, aDI). This was calculated
by expressing the OD for each subclass as a percentage of
the cumulative OD generated from all four subclasses, for
each individual patient. The mean OD, as well as the average
percentage of cumulative binding for all four IgG subclasses in
both aβ2GPI and aDI assays can be seen in Table 2.
IgG4 was the lowest detected subclass in both aβ2GPI and
aDI (p < 0.05 across all comparisons). In aβ2GPI assays, the
IgG1 subclass was the most predominant, followed by IgG2
and IgG3, with no statistically significant difference between
these three subclasses (Table 2, Figure 1A, p > 0.05 across all
comparisons). In aDI assays however, the percentage of IgG3
was significantly higher than both IgG1 and IgG2 (Table 2,
Figure 1B), demonstrating that in our patients, aβ2GPI and
aDI can be of a different subclass. The average percentage
of cumulative binding for all patients for each IgG subclass
is summarized as a pie distribution chart in Figure 2 (2A,
aβ2GPI and 2B, aDI). Raw OD values can be seen in the
Figure S1.
Analysing the patients individually, 12/18 patients positive
for aDI had the majority of their antibody binding specific to
the IgG3 subtype. In contrast, only 4/18 had the highest for
IgG1. In the aDI assay, over 50% of the cumulative total OD
was seen in the IgG3 subtype for 9/18 patients, and 4 of these
patients showed over 75% of their cumulative antibody binding
to be of the IgG3 subclass. Comparatively, only 1/18 showed
>50% of the cumulative binding for IgG1 subclass (51%) and no
patients showed >50% of cumulative antibody binding for either
IgG2 or IgG4. In contrast, when analyzing the aβ2GPI subclass
pattern, only 3/19 patients had >50% antibody binding for IgG3
whilst 7/19 has >50% cumulative antibody binding for IgG1,
and one patient showed >50% cumulative antibody binding
in IgG2.
Correlation analysis of each IgG subclass for the two antigens
revealed strong correlations between aβ2GPI and aDI of the
same subclass for: IgG1 (r = 0.61, Figure 3A), IgG2 (r = 0.81,
Figure 3B) and IgG4 (r = 0.85, data not shown) The difference
is highlighted in IgG3 where the correlation is much lower (r
= 0.45, Figure 3C), reflecting the increased level of IgG3 aDI
antibodies compared to the IgG3 aβ2GPI antibodies.
When stratified by clinical phenotype (thrombosis vs.
pregnancy morbidity), the results were very similar across all IgG
subclasses, with no clear association between a single subclass
and clinical history (data not shown). However, this may be
confounded by low patient numbers.
FIGURE 1 | (A) shows the distribution of OD as a percentage of cumulative OD for aβ2GPI antibodies, (B) shows the same measure for aDI antibodies. The increase
in IgG3 percentage can be seen in (B), this was significantly higher than any other subclass. Both panels show IgG4 significantly lower than any other subclass for
both antigens. *p < 0.05; ** p < 0.01; *** p < 0.001. IgG4 vs. IgG1, IgG2 or IgG3 in both (A) and (B) = p < 0.05.
TABLE 2 | This table contains the raw OD and the average percentage of the cumulative OD for each subclass against both antigens.
aβ2GPI aDI
Mean OD (±SD) Average % of cumulative
binding (±SD)
Mean OD (±SD) Average % of cumulative
binding (±SD)
IgG 1 0.6 (±0.7) 39.5 (±26.0) 0.3 (±0.6) 24.3 (±14.9)
IgG 2 0.31(±0.27) 26.4 (±15.7) 0.2 (±0.3) 19.5 (±12.7)
IgG 3 0.37 (±0.35) 29.9 (±19.1) 0.45 (±0.4) 53.5 (±21.0)
IgG 4 0.07 (±0.15) 4.1 (±4.5) 0.02 (±0.04) 2.5 (±3.3)
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FIGURE 2 | (A) shows the proportion of aβ2GPI OD associated with each subclass. As can be seen, IgG1 predominates in the aβ2GPI assay whilst IgG2 and IgG3
are similar. (B) shows the same proportions for aDI subclasses. It is clear here the predominant subclass is IgG3.
FIGURE 3 | Correlations of subclasses between antigens. The strongest correlations are seen for IgG1 (A, p = 0.0001, r = 0.61), IgG2 (B, p = 0.0001, r = 0.81) and
IgG4 (p = 0.0001, r = 0.85; data not shown). The weakest correlation is seen with the IgG3 subclass (C, p = 0.02, r = 0.45) reflecting the difference between the
antigens in the IgG3 distribution.
Total Levels of Each IgG Subclass Were
Similar in Patients With APS Than Controls
To exclude the possibility that the high IgG3 aDI levels in
patients with APS were simply a reflection of over-production
of total IgG3, we measured total levels of each subclass in 10
healthy controls and 12 patients with APS. As can be seen in
Figure 4, there are no significant differences between the two
groups for total IgG 2, IgG 3 and IgG 4, thus underlining
that the high IgG3 aDI levels we detected in patients are
indeed antigen-specific. IgG 1 was significantly different between
APS and HC, with lower levels in HC (p < 0.045) however,
removal of the outlier in the HC group (1.53) loses the
significance.
CONCLUSIONS
Our data suggests that antibodies to DI are of a different subclass
to antibodies against whole β2GPI. In our cohort, antibodies to
DI are predominantly IgG3, whilst antibodies to β2GPI are more
prominently IgG1.
Our results conflict with previous data, which suggested
an IgG2 class restriction for aβ2GPI antibodies. These studies
however, were 20 years ago and our ability to characterize
subclasses of IgG has improved, as has the methodology for
FIGURE 4 | Total capture IgG ELISA results demonstrate that there are no
significant differences in OD for IgG 2, IgG 3 and IgG 4 subclass in comparison
of APS patients to healthy controls (HC). Subclass IgG 1 shows significantly
lower levels in APS, however, removal of the outlier in the HC group shows no
significant difference between APS and HC.
detecting antibodies to both DI and β2GPI. The production
of subclass specific monoclonal antibodies has improved and
aβ2GPI antibody assays have been developed and refined in that
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time, although no consensus on the source of antigen exists.
Another possibility for the discrepancy between our results and
others’, is that by selecting for patients who are both aβ2GPI
and aDI positive, we have isolated a patient population with less
overall IgG2 aβ2GPI and an overall different serological profile.
We knowingly selected patients with positivity to both β2GPI
and DI, allowing us to directly compare the subclasses detected
in the two assays. The dominance of IgG1 and IgG3 subclasses
is interesting as these are heavily involved in complement
activation, particularly IgG3, and may offer an insight to the
mechanisms of pathogenesis in APS. Interestingly, a difference in
subclass between these antibodies may imply several mechanisms
are active in APS patients. The IgG subclasses differ in their
affinity to receptors, their half lives and their potential activity
in vivo.
It was expected that the aβ2GPI and aDI subclasses would
be similar, as β2GPI contains the aDI epitope, however, the
results are quite disparate. This would suggest that the aβ2GPI
assay does not necessarily detect all circulating aDI antibodies,
and indicates a clinical utility for the aDI assay in patients.
Indeed, recommendations for development, standardization and
application of aDI assays in APS have existed for some years
now, first highlighted at the 14th International Congress for
Antiphospholipid Antibodies (35). Of note, we reported good
qualitative and quantitative agreement between our IgG aDI
ELISA and the USDA approved chemiluminescent assay for
aDI, developed by Inova Diagnostics (36). Despite this, it is
possible that the structure or presentation of the protein on
the plate may have influenced the results presented. Ideally this
would be repeated in the fluid phase to confirm binding to
subclasses.
To guard against bias from abnormally high or low IgG
subclass concentrations, patient antibodies were tested along
with healthy controls the results of which showed similar
proportions of IgG subclass antibodies between patients and
controls. It could be argued that the use of another irrelevant
antigen would aid in proving that the effect seen is not just
a skewing of antibody production, however, we felt that (a)
given the aDI and aβ2GPI subclasses differed, and (b) similar
quantification was seen in the total IgG subclass ELISA, that this
was not required.
To conclude, our findings suggest that IgG aDI are of a
different subclass to aβ2GPI. While unexpected, our results may
demonstrate IgG subclass switching of aβ2GPI to aDI, or vice
versa, and thus epitope restriction or spreading respectively.
Importantly, our study highlights the potential for aDI testing
to stratify patients. Further studies are required to validate these
findings in larger patient cohorts. The ability of IgG1 aβ2GPI
vs. IgG3 aDI to exert pathogenic biological effects also warrants
investigation, as autoantibody skewness to specific IgG subclasses
may indicate an association of these antigen-specific antibodies
with clinical outcomes.
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